Clinical Trial ResultsUpdated VERSATILE-002 data continue to reinforce Versamune HPV's potential in advanced HNSCC.
Regulatory ProgressThe FDA recently announced clearance of an IND application to investigate the combination of Versamune MUC1 and PDS01ADC in MUC1-positive advanced colorectal carcinoma.
Safety ProfileNo new safety signals were identified, and grade 3 or higher treatment-related adverse events occurred in only 19% of patients.
Treatment EfficacyMedian overall survival of 30.0 months for the Versamune HPV/pembrolizumab combination exceeds typical outcomes for this patient population.